Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 30 Show results per page	View Search Criteria \| Help With Results


1.		Aromatase Inhibitor Clinical Trial

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Biomarker/Laboratory analysis, Treatment				Active				40 to 70				NIGMS				0412-14 UO1-GM61373-06, NCT00228956


2.		Second-Line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				not specified				Other				N07MAN Eudract 2007-007030-20, NCT00684216


3.		Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				65 and over				Other				0120070323 NCT00698971

Last Modified: 1/14/2009 First Published: 7/26/2003


4.		Phase III Randomized Study of Ovarian Function Suppression in Combination With Tamoxifen Versus Ovarian Function Suppression in Combination With Exemestane Versus Tamoxifen Alone in Premenopausal Women With Endocrine-Responsive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Premenopausal				NCI				IBCSG-2402 BIG-2-02, CALGB-IBCSG-2402, CAN-NCIC-IBCSG-2402, NCCTG-IBCSG-2402, NSABP-IBCSG-2402, SWOG-IBCSG-2402, NABCI-IBCSG-2402, UCLA-0403024-01, EU-20334, IBCSG-24-02, NCT00066690, EUDRACT-2004-000166-13

Last Modified: 1/14/2009 First Published: 7/26/2003


5.		Phase III Randomized Study of Triptorelin and Exemestane Versus Triptorelin and Tamoxifen in Premenopausal Women With Endocrine-Responsive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Premenopausal				NCI				IBCSG-25-02 BIG-3-02, NABCI-IBCSG-25-02, EU-20347, NCT00066703, EUDRACT-2004-000168-28

Last Modified: 1/6/2009 First Published: 4/23/2004


6.		Phase III Randomized Study of Exemestane in Postmenopausal Women at Increased Risk of Developing Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Prevention				Active				35 and over				Other, Pharmaceutical / Industry				CAN-NCIC-MAP3 PFIZER-EXEAPO-0028-150, ExCel, NCT00083174, MAP3


7.		Aromasin vs Arimidex Study As Initial Hormonal Therapy in Postmenopausal Women With Advanced/Recurrent Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				20 and over				Pharmaceutical / Industry				A5991048 NCT00143390

Last Modified: 9/12/2007 First Published: 11/4/2005


8.		Phase III Randomized Study of Fulvestrant With Versus Without Anastrozole Versus Exemestane Alone in Postmenopausal Women With Estrogen Receptor and/or Progesterone Receptor Positive Locally Advanced or Metastatic Breast Cancer That Relapsed or Progressed During Prior Treatment With Nonsteroidal Aromatase Inhibitors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Any age				Other				ICR-CTSU-SOFEA EU-20531, SSA-04Q200635, ISRCTN44195747, MREC-03677, EUDRACT-2004-000093-30, NCT00253422

Last Modified: 1/14/2009 First Published: 12/9/2005


9.		Phase III Randomized Study of Neoadjuvant Therapy Comprising Exemestane Versus Letrozole Versus Anastrozole in Postmenopausal Women With Estrogen Receptor Positive Stage II or III Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Postmenopausal				NCI				ACOSOG-Z1031 CALGB-ACOSOG-Z1031, SDC1, NCT00265759

Last Modified: 1/14/2009 First Published: 3/24/2006


10.		Phase III Randomized Study of Adjuvant Combination Chemotherapy and Hormonal Therapy Versus Adjuvant Hormonal Therapy Alone in Women With Previously Resected Axillary Node-Negative Breast Cancer With Various Levels of Risk for Recurrence (TAILORx Trial)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 75				NCI				ECOG-PACCT-1 SWOG-ECOG-PACCT-1, CALGB-ECOG-PACCT-1, NCCTG-ECOG-PACCT-1, NSABP-ECOG-PACCT-1, ACOSOG-ECOG-PACCT-1, CAN-NCIC-MAC12, PACCT-1, NCT00310180, TAILORx

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute